Growth Metrics

10x Genomics (TXG) Short term Debt (2018 - 2019)

10x Genomics recorded quarterly Short term Debt of $9.9 million in Q4 2019, up 33.85% quarter-over-quarter from $7.4 million in Q3 2019, and up 136.02% year-over-year from $4.2 million in Q4 2018.

10x Genomics' Short term Debt history runs 2 years deep, the most recent figure standing at $9.9 million for Q4 2019.

  • In Q4 2019, Short term Debt rose 136.02% year-over-year to $9.9 million; the TTM figure through Dec 2019 stood at $9.9 million (up 136.02% YoY), while the FY2019 annual figure was $9.9 million, up 136.02% from the prior year.
  • Short term Debt came in at $9.9 million for Q4 2019 at 10x Genomics, up from $7.4 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $9.9 million in Q4 2019 to a low of $4.2 million in Q4 2018.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Veeva Systems 30.85 Bn 24.28 Bn 622.47 Mn
2 BrightSpring Health Services 12.29 Bn 11.41 Bn 482.22 Mn
3 Healthequity 7.80 Bn 7.48 Bn 256.31 Mn
4 Hinge Health 4.82 Bn 4.51 Bn 154.23 Mn
5 Doximity 4.21 Bn 3.46 Bn 125.97 Mn
6 Waystar Holding 4.18 Bn 4.03 Bn 268.04 Mn
7 10x Genomics 3.78 Bn 3.24 Bn 106.18 Mn
8 Privia Health 2.65 Bn 2.28 Bn 595.71 Mn
9 Omnicell 1.95 Bn 1.78 Bn 140.36 Mn
10 Teladoc Health 1.42 Bn 672.39 Mn 562.57 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2019 9.88 Mn
Sep 30, 2019 7.38 Mn
Dec 31, 2018 4.19 Mn